{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:11:31Z","timestamp":1790997091603,"version":"4.1.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04334-4","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:04:16Z","timestamp":1774886656000},"page":"3668-3681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Circulating tumor DNA-based detection of molecular residual disease in isocitrate dehydrogenase-mutant cholangiocarcinoma for biomarker-guided therapy"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6159-7566","authenticated-orcid":false,"given":"Alexei Valerievich","family":"Yumashev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boymuradov","family":"Shuxrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasimov","family":"Khayotbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umid","family":"Kodirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziza","family":"Elmurodova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdualimov","family":"Rufat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilufar","family":"Urinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iroda","family":"Abduraxmonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"issue":"10","key":"4334_CR1","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/oncolo\/oyac150","volume":"27","author":"M Javle","year":"2022","unstructured":"Javle M, Lee S, Azad NS, Borad MJ, Kate Kelley R, Sivaraman S, et al. Temporal changes in cholangiocarcinoma incidence and mortality in the United States from 2001 to 2017. Oncologist. 2022;27(10):874\u201383. https:\/\/doi.org\/10.1093\/oncolo\/oyac150.","journal-title":"Oncologist"},{"issue":"9","key":"4334_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4334_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1146\/annurev-pathol-030220-020455","volume":"16","author":"PM Rodrigues","year":"2021","unstructured":"Rodrigues PM, Olaizola P, Paiva NA, Olaizola I, Agirre-Lizaso A, Landa A, et al. Pathogenesis of cholangiocarcinoma. Annu Rev Pathol. 2021;16:433\u201363. https:\/\/doi.org\/10.1146\/annurev-pathol-030220-020455.","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"4334_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261\u201380. https:\/\/doi.org\/10.1038\/nrgastro.2016.51.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"4334_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","volume":"17","author":"DR Borger","year":"2012","unstructured":"Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17(1):72\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2011-0386.","journal-title":"Oncologist"},{"issue":"1","key":"4334_CR6","doi-asserted-by":"publisher","first-page":"15820","DOI":"10.1038\/s41598-020-72810-0","volume":"10","author":"K Lee","year":"2020","unstructured":"Lee K, Song YS, Shin Y, Wen X, Kim Y, Cho N-Y, et al. Intrahepatic cholangiocarcinomas with IDH1\/2 mutation-associated hypermethylation at selective genes and their clinicopathological features. Sci Rep. 2020;10(1):15820. https:\/\/doi.org\/10.1038\/s41598-020-72810-0.","journal-title":"Sci Rep"},{"issue":"1","key":"4334_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41575-025-01153-w","volume":"23","author":"JM Banales","year":"2026","unstructured":"Banales JM, Rodrigues PM, Aff\u00f2 S, Andersen JB, Aspichueta P, Boulter L, et al. Cholangiocarcinoma 2026: status quo, unmet needs and priorities. Nat Rev Gastroenterol Hepatol. 2026;23(1):65\u201396. https:\/\/doi.org\/10.1038\/s41575-025-01153-w.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"4334_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"3","key":"4334_CR9","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143\u201352.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4334_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00876-y","volume":"9","author":"A Bartolomucci","year":"2025","unstructured":"Bartolomucci A, Nobrega M, Ferrier T, Dickinson K, Kaorey N, Nadeau A, et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. npj Precis Oncol. 2025;9(1):84. https:\/\/doi.org\/10.1038\/s41698-025-00876-y.","journal-title":"npj Precis Oncol"},{"issue":"3","key":"4334_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2174\/0109298665286952240212053723","volume":"31","author":"Y Zhu","year":"2024","unstructured":"Zhu Y. Plasma\/serum proteomics based on mass spectrometry. Protein Pept Lett. 2024;31(3):192\u2013208. https:\/\/doi.org\/10.2174\/0109298665286952240212053723.","journal-title":"Protein Pept Lett"},{"issue":"5","key":"4334_CR12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.2174\/0113892029301904240513045755","volume":"25","author":"C Lee","year":"2024","unstructured":"Lee C, An Y. Deciphering the genetic complexity of classical Hodgkin lymphoma: insights and effective strategies. Curr Genomics. 2024;25(5):334\u201342. https:\/\/doi.org\/10.2174\/0113892029301904240513045755.","journal-title":"Curr Genomics"},{"issue":"2","key":"4334_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2174\/0113892029319425240813074610","volume":"26","author":"F Li","year":"2025","unstructured":"Li F, Yang X, Wang X, Mi J, Mou X, Song L, et al. High-throughput sequencing reveals that BCR and TCR repertoires as potential prognostic biomarkers for pediatric patients with B-ALL. Curr Genomics. 2025;26(2):144\u201359. https:\/\/doi.org\/10.2174\/0113892029319425240813074610.","journal-title":"Curr Genomics"},{"issue":"1","key":"4334_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1566523223666230801090355","volume":"24","author":"GB Hiremath","year":"2024","unstructured":"Hiremath GB, Omkarbabu K, Kokate MH, Venkidasamy B, Krishnan M, Murugaiyan A. Development of oral bio-banks past, present and future; challenges and opportunities. Curr Gene Ther. 2024;24(1):2\u20133. https:\/\/doi.org\/10.2174\/1566523223666230801090355.","journal-title":"Curr Gene Ther"},{"issue":"7761","key":"4334_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","volume":"570","author":"S Cristiano","year":"2019","unstructured":"Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570(7761):385\u20139. https:\/\/doi.org\/10.1038\/s41586-019-1272-6.","journal-title":"Nature"},{"key":"4334_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100701","volume":"35","author":"KZY Myint","year":"2023","unstructured":"Myint KZY, Shimabuku M, Horio R, Kaneda M, Shimizu Y, Taguchi J. Identification of circulating tumour DNA (ctDNA) from the liquid biopsy results: findings from an observational cohort study. Cancer Treat Res Commun. 2023;35:100701. https:\/\/doi.org\/10.1016\/j.ctarc.2023.100701.","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"4334_CR17","doi-asserted-by":"publisher","first-page":"8760","DOI":"10.1038\/ncomms9760","volume":"6","author":"M Murtaza","year":"2015","unstructured":"Murtaza M, Dawson S-J, Pogrebniak K, Rueda OM, Provenzano E, Grant J, et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun. 2015;6(1):8760.","journal-title":"Nat Commun"},{"issue":"9","key":"4334_CR18","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/annonc\/mdu239","volume":"25","author":"L De Mattos-Arruda","year":"2014","unstructured":"De Mattos-Arruda L, Weigelt B, Cortes J, Won H, Ng C, Nuciforo P, et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol. 2014;25(9):1729\u201335.","journal-title":"Ann Oncol"},{"issue":"40","key":"4334_CR19","doi-asserted-by":"publisher","first-page":"E5503","DOI":"10.1073\/pnas.1508736112","volume":"112","author":"K Sun","year":"2015","unstructured":"Sun K, Jiang P, Chan KA, Wong J, Cheng YK, Liang RH, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A. 2015;112(40):E5503\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4334_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14121143","author":"S Ursprung","year":"2024","unstructured":"Ursprung S, Thaiss W, Beha J, M\u00f6ller Y, Malek NP, Beer M, et al. Standardized response assessment in patients with advanced cholangiocarcinoma treated with personalized therapy. J Pers Med. 2024. https:\/\/doi.org\/10.3390\/jpm14121143.","journal-title":"J Pers Med"},{"issue":"13","key":"4334_CR21","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/jnci\/djq187","volume":"102","author":"ZJ Reitman","year":"2010","unstructured":"Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010;102(13):932\u201341. https:\/\/doi.org\/10.1093\/jnci\/djq187.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"4334_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw4543","volume":"5","author":"S Tommasini-Ghelfi","year":"2019","unstructured":"Tommasini-Ghelfi S, Murnan K, Kouri FM, Mahajan AS, May JL, Stegh AH. Cancer-associated mutation and beyond: the emerging biology of isocitrate dehydrogenases in human disease. Sci Adv. 2019;5(5):eaaw4543. https:\/\/doi.org\/10.1126\/sciadv.aaw4543.","journal-title":"Sci Adv"},{"key":"4334_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/genes14091818","author":"BI Ruiz","year":"2023","unstructured":"Ruiz BI, Lowman XH, Yang Y, Fan Q, Wang T, Wu H, et al. Alpha-ketoglutarate regulates Tnfrsf12a\/Fn14 expression via histone modification and prevents cancer-induced cachexia. Genes. 2023. https:\/\/doi.org\/10.3390\/genes14091818.","journal-title":"Genes"},{"issue":"7539","key":"4334_CR24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature13981","volume":"518","author":"BW Carey","year":"2015","unstructured":"Carey BW, Finley LW, Cross JR, Allis CD, Thompson CB. Intracellular \u03b1-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature. 2015;518(7539):413\u20136. https:\/\/doi.org\/10.1038\/nature13981.","journal-title":"Nature"},{"issue":"3","key":"4334_CR25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s43018-020-0035-5","volume":"1","author":"TQ Tran","year":"2020","unstructured":"Tran TQ, Hanse EA, Habowski AN, Li H, Ishak Gabra MB, Yang Y, et al. \u03b1-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer. Nat Cancer. 2020;1(3):345\u201358. https:\/\/doi.org\/10.1038\/s43018-020-0035-5.","journal-title":"Nat Cancer"},{"issue":"18","key":"4334_CR26","doi-asserted-by":"publisher","first-page":"12967","DOI":"10.1074\/jbc.M112.396796","volume":"288","author":"PA Gameiro","year":"2013","unstructured":"Gameiro PA, Laviolette LA, Kelleher JK, Iliopoulos O, Stephanopoulos G. Cofactor balance by nicotinamide nucleotide transhydrogenase (NNT) coordinates reductive carboxylation and glucose catabolism in the tricarboxylic acid (TCA) cycle. J Biol Chem. 2013;288(18):12967\u201377. https:\/\/doi.org\/10.1074\/jbc.M112.396796.","journal-title":"J Biol Chem"},{"issue":"38","key":"4334_CR27","doi-asserted-by":"publisher","first-page":"39968","DOI":"10.1074\/jbc.M402260200","volume":"279","author":"HJ Koh","year":"2004","unstructured":"Koh HJ, Lee SM, Son BG, Lee SH, Ryoo ZY, Chang KT, et al. Cytosolic NADP+-dependent isocitrate dehydrogenase plays a key role in lipid metabolism. J Biol Chem. 2004;279(38):39968\u201374. https:\/\/doi.org\/10.1074\/jbc.M402260200.","journal-title":"J Biol Chem"},{"issue":"19","key":"4334_CR28","doi-asserted-by":"publisher","first-page":"16168","DOI":"10.1074\/jbc.M010120200","volume":"276","author":"SH Jo","year":"2001","unstructured":"Jo SH, Son MK, Koh HJ, Lee SM, Song IH, Kim YO, et al. Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP+-dependent isocitrate dehydrogenase. J Biol Chem. 2001;276(19):16168\u201376. https:\/\/doi.org\/10.1074\/jbc.M010120200.","journal-title":"J Biol Chem"},{"issue":"11","key":"4334_CR29","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/s0891-5849(02)00815-8","volume":"32","author":"SM Lee","year":"2002","unstructured":"Lee SM, Koh HJ, Park DC, Song BJ, Huh TL, Park JW. Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med. 2002;32(11):1185\u201396. https:\/\/doi.org\/10.1016\/s0891-5849(02)00815-8.","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"4334_CR30","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1073\/pnas.1618605114","volume":"114","author":"J Ye","year":"2017","unstructured":"Ye J, Gu Y, Zhang F, Zhao Y, Yuan Y, Hao Z, et al. IDH1 deficiency attenuates gluconeogenesis in mouse liver by impairing amino acid utilization. Proc Natl Acad Sci U S A. 2017;114(2):292\u20137. https:\/\/doi.org\/10.1073\/pnas.1618605114.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"4334_CR31","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1038\/cdd.2015.38","volume":"22","author":"M Itsumi","year":"2015","unstructured":"Itsumi M, Inoue S, Elia AJ, Murakami K, Sasaki M, Lind EF, et al. Idh1 protects murine hepatocytes from endotoxin-induced oxidative stress by regulating the intracellular NADP(+)\/NADPH ratio. Cell Death Differ. 2015;22(11):1837\u201345. https:\/\/doi.org\/10.1038\/cdd.2015.38.","journal-title":"Cell Death Differ"},{"key":"4334_CR32","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.036426","author":"AS Findlay","year":"2018","unstructured":"Findlay AS, Carter RN, Starbuck B, McKie L, Nov\u00e1kov\u00e1 K, Budd PS, et al. Mouse Idh3a mutations cause retinal degeneration and reduced mitochondrial function. Dis Model Mech. 2018. https:\/\/doi.org\/10.1242\/dmm.036426.","journal-title":"Dis Model Mech"},{"issue":"5","key":"4334_CR33","doi-asserted-by":"publisher","first-page":"328","DOI":"10.5582\/bst.2020.03240","volume":"14","author":"W Zhang","year":"2020","unstructured":"Zhang W, Zhou H, Wang Y, Zhang Z, Cao G, Song T, et al. Systemic treatment of advanced or recurrent biliary tract cancer. Biosci Trends. 2020;14(5):328\u201341. https:\/\/doi.org\/10.5582\/bst.2020.03240.","journal-title":"Biosci Trends"},{"issue":"5","key":"4334_CR34","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/hep.32424","volume":"75","author":"MJ Wu","year":"2022","unstructured":"Wu MJ, Shi L, Merritt J, Zhu AX, Bardeesy N. Biology of IDH mutant cholangiocarcinoma. Hepatology. 2022;75(5):1322\u201337. https:\/\/doi.org\/10.1002\/hep.32424.","journal-title":"Hepatology"},{"issue":"117","key":"4334_CR35","first-page":"373","volume":"21","author":"T Fujii","year":"2016","unstructured":"Fujii T, Khawaja MR, DiNardo CD, Atkins JT, Janku F. Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med. 2016;21(117):373\u201380.","journal-title":"Discov Med"},{"key":"4334_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100356","volume":"27","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Ricci AD, Brandi G. IDH inhibitors in advanced cholangiocarcinoma: another arrow in the quiver? Cancer Treat Res Commun. 2021;27:100356. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100356.","journal-title":"Cancer Treat Res Commun"},{"key":"4334_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810869","author":"G Brandi","year":"2022","unstructured":"Brandi G, Rizzo A. IDH inhibitors and immunotherapy for biliary tract cancer: a marriage of convenience? Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231810869.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4334_CR38","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1172\/jci90644","volume":"127","author":"G Kohanbash","year":"2017","unstructured":"Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest. 2017;127(4):1425\u201337. https:\/\/doi.org\/10.1172\/jci90644.","journal-title":"J Clin Invest"},{"issue":"7","key":"4334_CR39","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","volume":"181","author":"F Klemm","year":"2020","unstructured":"Klemm F, Maas RR, Bowman RL, Kornete M, Soukup K, Nassiri S, et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell. 2020;181(7):1643-60.e17. https:\/\/doi.org\/10.1016\/j.cell.2020.05.007.","journal-title":"Cell"},{"issue":"8","key":"4334_CR40","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","volume":"24","author":"L Bunse","year":"2018","unstructured":"Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med. 2018;24(8):1192\u2013203. https:\/\/doi.org\/10.1038\/s41591-018-0095-6.","journal-title":"Nat Med"},{"issue":"3","key":"4334_CR41","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2159-8290.Cd-21-1077","volume":"12","author":"MJ Wu","year":"2022","unstructured":"Wu MJ, Shi L, Dubrot J, Merritt J, Vijay V, Wei TY, et al. Mutant IDH inhibits IFN\u03b3-TET2 signaling to promote immunoevasion and tumor maintenance in Cholangiocarcinoma. Cancer Discov. 2022;12(3):812\u201335. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-1077.","journal-title":"Cancer Discov"},{"issue":"6","key":"4334_CR42","doi-asserted-by":"publisher","first-page":"996","DOI":"10.21037\/jgo.2016.09.10","volume":"7","author":"R Agarwal","year":"2016","unstructured":"Agarwal R, Sendilnathan A, Siddiqi NI, Gulati S, Ghose A, Xie C, et al. Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States. J Gastrointest Oncol. 2016;7(6):996\u20131003.","journal-title":"J Gastrointest Oncol"},{"issue":"8","key":"4334_CR43","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid"},{"issue":"10391","key":"4334_CR44","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023;401(10391):1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"The Lancet"},{"issue":"12","key":"4334_CR45","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s11864-025-01365-x","volume":"26","author":"M Siwek","year":"2025","unstructured":"Siwek M, Chmiel P, Grabowska H, Gr\u0105t M, Kraj L. Second-line treatment in cholangiocarcinoma - current state of the art and future perspectives. Curr Treat Options Oncol. 2025;26(12):1061\u201377. https:\/\/doi.org\/10.1007\/s11864-025-01365-x.","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"4334_CR46","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690\u2013701. https:\/\/doi.org\/10.1016\/S1470-2045(21)00027-9.","journal-title":"Lancet Oncol"},{"issue":"6","key":"4334_CR47","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/s1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796\u2013807. https:\/\/doi.org\/10.1016\/s1470-2045(20)30157-1.","journal-title":"Lancet Oncol"},{"key":"4334_CR48","doi-asserted-by":"publisher","first-page":"175883592311715","DOI":"10.1177\/17588359231171574","volume":"15","author":"M Rimini","year":"2023","unstructured":"Rimini M, Burgio V, Antonuzzo L, Rimassa L, Oneda E, Sold\u00e0 C, et al. Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience. Ther Adv Med Oncol. 2023;15:17588359231171574. https:\/\/doi.org\/10.1177\/17588359231171574.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"4334_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00304-5","volume":"6","author":"JM Cleary","year":"2022","unstructured":"Cleary JM, Rouaisnel B, Daina A, Raghavan S, Roller LA, Huffman BM, et al. Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma. npj Precis Oncol. 2022;6(1):61. https:\/\/doi.org\/10.1038\/s41698-022-00304-5.","journal-title":"npj Precis Oncol"},{"key":"4334_CR50","doi-asserted-by":"publisher","DOI":"10.1101\/2025.07.19.25331848","author":"MK Nguyen","year":"2025","unstructured":"Nguyen MK, Jelinek M, Singh A, Isett B, Myers ES, Mullett SJ, et al. Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations. medRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.07.19.25331848.","journal-title":"medRxiv"},{"key":"4334_CR51","doi-asserted-by":"crossref","unstructured":"Tsang ES, O'Kane GM, Knox JJ, Chen EX. A phase II study of olaparib and durvalumab in patients with IDH-mutated cholangiocarcinoma. Am Soc Clin Oncol; 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.4099"},{"issue":"4","key":"4334_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35755","volume":"131","author":"M Cecchini","year":"2025","unstructured":"Cecchini M, Pilat MJ, Uboha N, Azad NS, Cho M, Davis EJ, et al. Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial. Cancer. 2025;131(4):e35755. https:\/\/doi.org\/10.1002\/cncr.35755.","journal-title":"Cancer"},{"issue":"11","key":"4334_CR53","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7(11):1669\u201377. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3836.","journal-title":"JAMA Oncol"},{"issue":"16_suppl","key":"4334_CR54","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2024.42.16_suppl.2013","volume":"42","author":"X Wang","year":"2024","unstructured":"Wang X, Ellenbogen Y, Mojica C, Matos GDR, Alsajjan R, Ramos R, et al. A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas. J Clin Oncol. 2024;42(16_suppl):2013. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.2013.","journal-title":"J Clin Oncol"},{"issue":"23","key":"4334_CR55","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1158\/1078-0432.Ccr-25-0174","volume":"31","author":"JJ Harding","year":"2025","unstructured":"Harding JJ, Oh DY, Mercade TM, Goyal L, Varkaris A, Palmieri LJ, et al. Final results from a first-in-human phase i study of the dual isocitrate dehydrogenase (IDH) 1\/2 inhibitor, LY3410738, in advanced solid tumors harboring IDH1 or IDH2 mutations. Clin Cancer Res. 2025;31(23):4920\u201332. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-0174.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4334_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ph14060596","volume":"14","author":"E Bohers","year":"2021","unstructured":"Bohers E, Viailly PJ, Jardin F. cfDNA sequencing: technological approaches and bioinformatic issues. Pharm (Basel). 2021;14(6):0596. https:\/\/doi.org\/10.3390\/ph14060596.","journal-title":"Pharm (Basel)"},{"issue":"3","key":"4334_CR57","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40291-019-00390-5","volume":"23","author":"RI Chin","year":"2019","unstructured":"Chin RI, Chen K, Usmani A, Chua C, Harris PK, Binkley MS, et al. Detection of solid tumor molecular residual disease (MRD) using circulating tumor DNA (ctDNA). Mol Diagn Ther. 2019;23(3):311\u201331. https:\/\/doi.org\/10.1007\/s40291-019-00390-5.","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"4334_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-025-00921-8","volume":"5","author":"P van der Leest","year":"2025","unstructured":"van der Leest P, Rozendal P, Rifaela N, van der Wekken AJ, Kievit H, de Jager VD, et al. Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients. Commun Med. 2025;5(1):204. https:\/\/doi.org\/10.1038\/s43856-025-00921-8.","journal-title":"Commun Med"},{"issue":"3","key":"4334_CR59","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1373\/clinchem.2017.277897","volume":"64","author":"G Greiner","year":"2018","unstructured":"Greiner G, Gurbisz M, Ratzinger F, Witzeneder N, Simonitsch-Klupp I, Mitterbauer-Hohendanner G, et al. Digital PCR: a sensitive and precise method for KIT D816V quantification in mastocytosis. Clin Chem. 2018;64(3):547\u201355. https:\/\/doi.org\/10.1373\/clinchem.2017.277897.","journal-title":"Clin Chem"},{"issue":"11","key":"4334_CR60","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.4103\/1673-5374.371356","volume":"18","author":"WS Lee","year":"2023","unstructured":"Lee WS, Lockhart PJ. Utility of droplet digital polymerase chain reaction for studying somatic mosaicism: brain malformations and beyond. Neural Regen Res. 2023;18(11):2389\u201390. https:\/\/doi.org\/10.4103\/1673-5374.371356.","journal-title":"Neural Regen Res"},{"issue":"1","key":"4334_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-022-01335-6","volume":"10","author":"M Wolter","year":"2022","unstructured":"Wolter M, Felsberg J, Malzkorn B, Kaulich K, Reifenberger G. Droplet digital PCR-based analyses for robust, rapid, and sensitive molecular diagnostics of gliomas. Acta Neuropathol Commun. 2022;10(1):42. https:\/\/doi.org\/10.1186\/s40478-022-01335-6.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"4334_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39874-0","volume":"13","author":"V Pablo-Fontecha","year":"2023","unstructured":"Pablo-Fontecha V, Hern\u00e1ndez-Ill\u00e1n E, Reparaz A, Asensio E, Morata J, Tonda R, et al. Quantification of rare somatic single nucleotide variants by droplet digital PCR using superselective primers. Sci Rep. 2023;13(1):18997. https:\/\/doi.org\/10.1038\/s41598-023-39874-0.","journal-title":"Sci Rep"},{"issue":"7","key":"4334_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/cells12071068","volume":"12","author":"AA J\u00e1come","year":"2023","unstructured":"J\u00e1come AA, Johnson B. Minimal residual disease in colorectal cancer: are we finding the needle in a haystack? Cells. 2023;12(7):1068. https:\/\/doi.org\/10.3390\/cells12071068.","journal-title":"Cells"},{"key":"4334_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.763790","volume":"11","author":"Y Peng","year":"2021","unstructured":"Peng Y, Mei W, Ma K, Zeng C. Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives. Front Oncol. 2021;11:763790. https:\/\/doi.org\/10.3389\/fonc.2021.763790.","journal-title":"Front Oncol"},{"issue":"20","key":"4334_CR65","doi-asserted-by":"publisher","first-page":"6026","DOI":"10.1158\/1078-0432.Ccr-19-0152.","volume":"25","author":"M Coakley","year":"2019","unstructured":"Coakley M, Garcia-Murillas I, Turner NC. Molecular residual disease and adjuvant trial design in solid tumors. Clin Cancer Res. 2019;25(20):6026\u201334. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-0152.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"4334_CR66","doi-asserted-by":"publisher","first-page":"11521","DOI":"10.3390\/ijms231911521","volume":"23","author":"K Watanabe","year":"2022","unstructured":"Watanabe K, Nakamura T, Kimura Y, Motoya M, Kojima S, Kuraya T, et al. Tumor-informed approach improved ctDNA detection rate in resected pancreatic cancer. Int J Mol Sci. 2022;23(19):11521.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4334_CR67","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/cas.16446","volume":"116","author":"T Sasaki","year":"2025","unstructured":"Sasaki T, Hiraki H, Yashima-Abo A, Nagashima H, Endo F, Yaegashi M, et al. Comprehensive genome profiling-initiated tumor-informed circulating tumor DNA monitoring for patients with advanced cancer. Cancer Sci. 2025;116(3):764\u201374.","journal-title":"Cancer Sci"},{"key":"4334_CR68","doi-asserted-by":"publisher","DOI":"10.1200\/po.21.00197","volume":"6","author":"M Lapin","year":"2022","unstructured":"Lapin M, Huang HJ, Chagani S, Javle M, Shroff RT, Pant S, et al. Monitoring of dynamic changes and clonal evolution in circulating tumor DNA from patients with IDH-mutated cholangiocarcinoma treated with isocitrate dehydrogenase inhibitors. JCO Precis Oncol. 2022;6:e2100197. https:\/\/doi.org\/10.1200\/po.21.00197.","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"4334_CR69","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jhep.2024.10.020","volume":"82","author":"S Hwang","year":"2025","unstructured":"Hwang S, Woo S, Kang B, Kang H, Kim JS, Lee SH, et al. Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer. J Hepatol. 2025;82(4):649\u201357. https:\/\/doi.org\/10.1016\/j.jhep.2024.10.020.","journal-title":"J Hepatol"},{"issue":"7761","key":"4334_CR70","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","volume":"570","author":"S Cristiano","year":"2019","unstructured":"Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570(7761):385\u20139.","journal-title":"Nature"},{"issue":"9","key":"4334_CR71","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375.","volume":"47","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003\u201310. https:\/\/doi.org\/10.1038\/ng.3375.","journal-title":"Nat Genet"},{"issue":"11","key":"4334_CR72","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.annonc.2024.08.2240.","volume":"35","author":"K Kataoka","year":"2024","unstructured":"Kataoka K, Mori K, Nakamura Y, Watanabe J, Akazawa N, Hirata K, et al. Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY. Ann Oncol. 2024;35(11):1015\u201325. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2240.","journal-title":"Ann Oncol"},{"issue":"11","key":"4334_CR73","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6.","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med. 2024;30(11):3272\u201383. https:\/\/doi.org\/10.1038\/s41591-024-03254-6.","journal-title":"Nat Med"},{"issue":"3_suppl","key":"4334_CR74","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1200\/JCO.2024.42.3_suppl.9","volume":"42","author":"PM Kasi","year":"2024","unstructured":"Kasi PM, Aushev VN, Ensor J, Langer N, Wang CG, Cannon TL, et al. Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II\/III colorectal cancer (CRC): interim analysis of BESPOKE CRC study. J Clin Oncol. 2024;42(3_suppl):9. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.9.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4334_CR75","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.annonc.2025.01.021","volume":"36","author":"I Garcia-Murillas","year":"2025","unstructured":"Garcia-Murillas I, Abbott CW, Cutts RJ, Boyle SM, Pugh J, Keough KC, et al. Whole genome sequencing-powered ctDNA sequencing for breast cancer detection. Ann Oncol. 2025;36(6):673\u201381. https:\/\/doi.org\/10.1016\/j.annonc.2025.01.021.","journal-title":"Ann Oncol"},{"issue":"4","key":"4334_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104296","volume":"10","author":"W Janni","year":"2025","unstructured":"Janni W, Rack B, Friedl TWP, Hartkopf AD, Wiesm\u00fcller L, Pfister K, et al. Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay. ESMO Open. 2025;10(4):104296. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104296.","journal-title":"ESMO Open"},{"key":"4334_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2024.102060","volume":"54","author":"F Hassan","year":"2024","unstructured":"Hassan F, Wang JH, O\u2019Leary DP, Corrigan M, Redmond HP. Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer. Surg Oncol. 2024;54:102060. https:\/\/doi.org\/10.1016\/j.suronc.2024.102060.","journal-title":"Surg Oncol"},{"issue":"10","key":"4334_CR78","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.ccell.2023.09.007","volume":"41","author":"Y Pan","year":"2023","unstructured":"Pan Y, Zhang JT, Gao X, Chen ZY, Yan B, Tan PX, et al. Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients. Cancer Cell. 2023;41(10):1763-73.e4. https:\/\/doi.org\/10.1016\/j.ccell.2023.09.007.","journal-title":"Cancer Cell"},{"issue":"5","key":"4334_CR79","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","volume":"33","author":"D Gale","year":"2022","unstructured":"Gale D, Heider K, Ruiz-Valdepenas A, Hackinger S, Perry M, Marsico G, et al. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann Oncol. 2022;33(5):500\u201310. https:\/\/doi.org\/10.1016\/j.annonc.2022.02.007.","journal-title":"Ann Oncol"},{"issue":"346","key":"4334_CR80","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92. https:\/\/doi.org\/10.1126\/scitranslmed.aaf6219.","journal-title":"Sci Transl Med"},{"key":"4334_CR81","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000006887","author":"SA Cohen","year":"2025","unstructured":"Cohen SA, Aushev VN, Laliotis G, Jabbal IS, Nagarajan A, Wang C, et al. Real-world monitoring of ctDNA reliably predicts cancer recurrence and treatment efficacy in patients with resected stages I-III colon cancer. Ann Surg. 2025. https:\/\/doi.org\/10.1097\/sla.0000000000006887.","journal-title":"Ann Surg"},{"key":"4334_CR82","doi-asserted-by":"publisher","DOI":"10.1200\/po-24-00934","volume":"9","author":"M Abdelrahim","year":"2025","unstructured":"Abdelrahim M, Mejia A, Esmail A, Barrera Gutierrez JC, Ouf M, Franses JW, et al. Feasibility of personalized and tumor-informed circulating tumor DNA assay for early recurrence detection in patients with hepatocellular carcinoma. JCO Precis Oncol. 2025;9:e2400934. https:\/\/doi.org\/10.1200\/po-24-00934.","journal-title":"JCO Precis Oncol"},{"key":"4334_CR83","doi-asserted-by":"publisher","first-page":"1119744","DOI":"10.3389\/fonc.2023.1119744","volume":"13","author":"Y Xu","year":"2023","unstructured":"Xu Y, Cai J, Zhong K, Wen Y, Cai L, He G, et al. Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection. Front Oncol. 2023;13:1119744. https:\/\/doi.org\/10.3389\/fonc.2023.1119744.","journal-title":"Front Oncol"},{"issue":"6","key":"4334_CR84","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/s43018-025-00960-z","volume":"6","author":"J Mart\u00edn-Arana","year":"2025","unstructured":"Mart\u00edn-Arana J, Gimeno-Valiente F, Henriksen TV, Garc\u00eda-Mic\u00f3 B, Mart\u00ednez-Castedo B, Gambardella V, et al. Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer. Nat Cancer. 2025;6(6):1000\u201316. https:\/\/doi.org\/10.1038\/s43018-025-00960-z.","journal-title":"Nat Cancer"},{"issue":"1","key":"4334_CR85","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1245\/s10434-015-4642-9","volume":"23","author":"G Spolverato","year":"2016","unstructured":"Spolverato G, Kim Y, Alexandrescu S, Marques HP, Lamelas J, Aldrighetti L, et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol. 2016;23(1):235\u201343.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"4334_CR86","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/hepr.13951","volume":"53","author":"H Maki","year":"2023","unstructured":"Maki H, Kawaguchi Y, Nagata R, Mihara Y, Ichida A, Ishizawa T, et al. Conditional recurrence analysis of intrahepatic cholangiocarcinoma: changes in recurrence rate and survival after recurrence resection by disease-free interval. Hepatol Res. 2023;53(12):1224\u201334. https:\/\/doi.org\/10.1111\/hepr.13951.","journal-title":"Hepatol Res"},{"issue":"2_suppl","key":"4334_CR87","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1200\/JCO.2026.44.2_suppl.598","volume":"44","author":"R Gelfer","year":"2026","unstructured":"Gelfer R, Harvey R, Drill EN, Balachandran VP, D\u2019Angelica MI, Drebin JA, et al. Evaluating the prognostic impact of IDH mutations in intrahepatic cholangiocarcinoma. J Clin Oncol. 2026;44(2_suppl):598. https:\/\/doi.org\/10.1200\/JCO.2026.44.2_suppl.598.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4334_CR88","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5(8):1124\u201331.","journal-title":"JAMA Oncol"},{"issue":"16_suppl","key":"4334_CR89","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1200\/JCO.2022.40.16_suppl.4019","volume":"40","author":"C Yoo","year":"2022","unstructured":"Yoo C, Jeong H, Kim K-P, Hwang DW, Lee J-H, Kim K-H, et al. Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): a multicenter, open-label, randomized, phase 2 study (STAMP). J Clin Oncol. 2022;40(16_suppl):4019. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4019.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4334_CR90","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jhep.2024.10.043","volume":"82","author":"C Yoo","year":"2025","unstructured":"Yoo C, Jeong H, Jeong JH, Kim KP, Lee S, Ryoo BY, et al. Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma. J Hepatol. 2025;82(5):861\u201370. https:\/\/doi.org\/10.1016\/j.jhep.2024.10.043.","journal-title":"J Hepatol"},{"issue":"1","key":"4334_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0341432","volume":"21","author":"Y Park","year":"2026","unstructured":"Park Y, Kim KS, Jo H, Kim H-P, Kyung DS, Yoo Y, et al. Feasibility of tumor-informed circulating tumor DNA for detecting minimal residual disease in surgically resected biliary tract cancer. PLoS ONE. 2026;21(1):e0341432. https:\/\/doi.org\/10.1371\/journal.pone.0341432.","journal-title":"PLoS ONE"},{"issue":"2","key":"4334_CR92","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/jgh.70208","volume":"41","author":"H Yoon","year":"2026","unstructured":"Yoon H, Yoo C. Systemic therapy for advanced biliary tract cancers in 2026: current standard of care and emerging therapeutic strategies. J Gastroenterol Hepatol. 2026;41(2):516\u201331. https:\/\/doi.org\/10.1111\/jgh.70208.","journal-title":"J Gastroenterol Hepatol"},{"issue":"15_suppl","key":"4334_CR93","doi-asserted-by":"publisher","first-page":"11526","DOI":"10.1200\/JCO.2017.35.15_suppl.11526","volume":"35","author":"P Razavi","year":"2017","unstructured":"Razavi P, Li BT, Hou C, Shen R, Venn O, Lim RS, et al. Cell-free DNA (cfDNA) mutations from clonal hematopoiesis: implications for interpretation of liquid biopsy tests. J Clin Oncol. 2017;35(15_suppl):11526. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.11526.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4334_CR94","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2643-3230.Bcd-23-0195","volume":"5","author":"N Landberg","year":"2024","unstructured":"Landberg N, K\u00f6hnke T, Feng Y, Nakauchi Y, Fan AC, Linde MH, et al. IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation. Blood Cancer Discov. 2024;5(2):114\u201331. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-23-0195.","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"4334_CR95","doi-asserted-by":"publisher","DOI":"10.3844\/ojbsci.2022.10.17","volume":"22","author":"RM Ualiyeva","year":"2022","unstructured":"Ualiyeva RM, Zhangazin SB, Altayeva IB. Structural organization of vitelline cells of trematode with undifferentiated body of Azygia Lucii (Muller, 1776). Online J Biol Sci. 2022;22(1):10.17. https:\/\/doi.org\/10.3844\/ojbsci.2022.10.17.","journal-title":"Online J Biol Sci"},{"issue":"11","key":"4334_CR96","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jamaoncol.2018.2297","volume":"4","author":"RN Ptashkin","year":"2018","unstructured":"Ptashkin RN, Mandelker DL, Coombs CC, Bolton K, Yelskaya Z, Hyman DM, et al. Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors. JAMA Oncol. 2018;4(11):1589\u201393. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2297.","journal-title":"JAMA Oncol"},{"key":"4334_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082277","author":"HT Chan","year":"2020","unstructured":"Chan HT, Chin YM, Nakamura Y, Low SK. Clonal hematopoiesis in liquid biopsy: from biological noise to valuable clinical implications. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12082277.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4334_CR98","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/bloodadvances.2025017293","volume":"10","author":"AC Parker","year":"2026","unstructured":"Parker AC, Van Amburg JC, Pershad Y, Ong DA, Hoey KJ, Farady CJ, et al. Accurate and reliable detection of clonal hematopoiesis in plasma cell-free DNA. Blood Adv. 2026;10(2):413\u20137. https:\/\/doi.org\/10.1182\/bloodadvances.2025017293.","journal-title":"Blood Adv"},{"key":"4334_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13100312","author":"S Cabello-Aguilar","year":"2025","unstructured":"Cabello-Aguilar S, Vendrell JA, Solassol J. Real-world technical hurdles of ctDNA NGS analysis: lessons from clinical implementation. Diseases. 2025. https:\/\/doi.org\/10.3390\/diseases13100312.","journal-title":"Diseases"},{"issue":"6","key":"4334_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006284","volume":"11","author":"NP Semenkovich","year":"2023","unstructured":"Semenkovich NP, Szymanski JJ, Earland N, Chauhan PS, Pellini B, Chaudhuri AA. Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA. J Immunother Cancer. 2023;11(6):e006284. https:\/\/doi.org\/10.1136\/jitc-2022-006284.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"4334_CR101","doi-asserted-by":"publisher","first-page":"340","DOI":"10.12968\/bjcn.2025.0038","volume":"30","author":"C Hogan","year":"2025","unstructured":"Hogan C. A discovery into the levels of work engagement of young Irish nurses working in post COVID-19 Australia. Br J Community Nurs. 2025;30(7):340\u20134. https:\/\/doi.org\/10.12968\/bjcn.2025.0038.","journal-title":"Br J Community Nurs"},{"issue":"1","key":"4334_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49860-0","volume":"9","author":"TJ Ettrich","year":"2019","unstructured":"Ettrich TJ, Schwerdel D, Dolnik A, Beuter F, Bl\u00e4tte TJ, Schmidt SA, et al. Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information. Sci Rep. 2019;9(1):13261. https:\/\/doi.org\/10.1038\/s41598-019-49860-0.","journal-title":"Sci Rep"},{"key":"4334_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050844","author":"T Rachman","year":"2024","unstructured":"Rachman T, Bartlett D, LaFramboise W, Wagner P, Schwartz R, Carja O. Modeling the effect of spatial structure on solid tumor evolution and circulating tumor DNA composition. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16050844.","journal-title":"Cancers (Basel)"},{"key":"4334_CR104","doi-asserted-by":"publisher","DOI":"10.1101\/2023.09.30.23296390","author":"V Efthymiou","year":"2023","unstructured":"Efthymiou V, Queenan N, Haas M, Naegele S, Goss D, Faden DL. Circulating tumor DNA in the immediate post-operative setting. medRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.09.30.23296390.","journal-title":"medRxiv"},{"key":"4334_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225698","author":"L Larrib\u00e8re","year":"2021","unstructured":"Larrib\u00e8re L, Martens UM. Advantages and challenges of using ctDNA NGS to assess the presence of minimal residual disease (MRD) in solid tumors. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13225698.","journal-title":"Cancers (Basel)"},{"key":"4334_CR106","doi-asserted-by":"publisher","DOI":"10.3844\/ojbsci.2023.124.132","author":"R Ualiyeva","year":"2023","unstructured":"Ualiyeva R. Functional role of vitelline glands and Mehlis gland in the process of resistant egg shell formation in trematodes. Online J Biol Sci. 2023. https:\/\/doi.org\/10.3844\/ojbsci.2023.124.132.","journal-title":"Online J Biol Sci"},{"key":"4334_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00851","volume":"9","author":"A Petrackova","year":"2019","unstructured":"Petrackova A, Vasinek M, Sedlarikova L, Dyskova T, Schneiderova P, Novosad T, et al. Standardization of sequencing coverage depth in NGS: recommendation for detection of clonal and subclonal mutations in cancer diagnostics. Front Oncol. 2019;9:851. https:\/\/doi.org\/10.3389\/fonc.2019.00851.","journal-title":"Front Oncol"},{"key":"4334_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2019.100901","volume":"28","author":"YW Cheng","year":"2019","unstructured":"Cheng YW, Stefaniuk C, Jakubowski MA. Real-time PCR and targeted next-generation sequencing in the detection of low level EGFR mutations: instructive case analyses. Respir Med Case Rep. 2019;28:100901. https:\/\/doi.org\/10.1016\/j.rmcr.2019.100901.","journal-title":"Respir Med Case Rep"},{"key":"4334_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27031569","author":"N Charbel","year":"2026","unstructured":"Charbel N, Rizkallah J, Bal MN, El Masri A, Armache E, Ghezzawi M, et al. Circulating tumor DNA in melanoma: advances in detection, clinical applications, and integration with emerging technologies. Int J Mol Sci. 2026. https:\/\/doi.org\/10.3390\/ijms27031569.","journal-title":"Int J Mol Sci"},{"key":"4334_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152520","author":"N Vojjala","year":"2025","unstructured":"Vojjala N, Gibatova V, Shah RN, Singal S, Prabhu R, Krishnamoorthy G, et al. Integrating circulating tumor DNA into clinical management of colorectal cancer: practical implications and therapeutic challenges. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17152520.","journal-title":"Cancers (Basel)"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04334-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04334-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04334-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T03:22:54Z","timestamp":1787455374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04334-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":110,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["4334"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04334-4","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no relevant financial or nonfinancial interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}